Medicinal Plant–Mediated Modulation of Akkermansia muciniphila : Mechanisms, Evidence, and Translational Perspectives

Akkermansia muciniphila is a mucin-degrading member of the human gut microbiota that has attracted considerable interest because of its associations with intestinal barrier integrity, immune regulation, and metabolic homeostasis. Although direct supplementation and dietary manipulation have been investigated, increasing evidence indicates that medicinal plants, herbal preparations, dietary phytochemicals, and plant-derived carbohydrates may also modify its abundance or ecological activity. This narrative review critically examines how medicinal plants and plant-derived compounds modulate A. muciniphila and evaluates the biological mechanisms, associated host outcomes, evidence strength, and translational relevance of these interactions. Literature was identified from PubMed/MEDLINE, Google Scholar, and additional bibliographic sources using combinations of terms related to A. muciniphila , gut microbiota, medicinal plants, herbal medicine, phytochemicals, polyphenols, polysaccharides, prebiotics, intestinal barrier function, inflammation, obesity, diabetes, and metabolic health. The present article is a narrative review and therefore does not claim a formal systematic-review or meta-analytic methodology. Relevant evidence was synthesized according to intervention type, model, mechanism, and evidence level. Preclinical studies summarized in the source literature indicate that several medicinal plants and plant-derived constituents including Abelmoschus manihot flavones, Agave salmiana saponins, Antrodia cinnamomea , Artemisia asiatica , berberine, Boswellia serrata constituents, Bofutsushosan, Gastrodia elata polysaccharides, rhubarb, Rhizoma Coptidis alkaloids, Platycodon grandiflorus, andrographolide, diosmin, and green tea can increase A. muciniphila abundance or create an intestinal environment favorable to its persistence. Proposed mechanisms include enhanced mucus production, epithelial-barrier support, SCFA generation, microbial cross-feeding, bile-acid signaling, and modulation of inflammatory pathways. Human evidence is substantially more limited and heterogeneous. Medicinal plants and plant-derived compounds represent promising candidates for microbiota-directed strategies involving A. muciniphila , but current evidence is predominantly preclinical. Changes in A. muciniphila abundance should not be interpreted as proof of causality, therapeutic efficacy, or safety. Standardized botanical preparations, strain-aware microbiome analyses, mechanistic studies, and adequately powered clinical trials are required before clinical translation.